NPPB and COVID-19: This study provided the first evidence that PAR-1 levels rise in COVID-19-affected T2DM patients, and it identified a positive correlation between serum BMI, PAR-1 levels, CRP, HbA1c, D-dimer, homocysteine, NT-proBNP, and other inflammatory mediators.